Mason Carrico
Stock Analyst at Stephens & Co.
(1.73)
# 3,133
Out of 4,856 analysts
81
Total ratings
29.41%
Success rate
-9.91%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Reiterates: Overweight | $67 | $43.30 | +54.73% | 2 | May 22, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $105 | $82.66 | +27.03% | 8 | May 20, 2025 | |
| PACB Pacific Biosciences of California | Reiterates: Overweight | $1.8 | $1.14 | +57.89% | 5 | May 15, 2025 | |
| TXG 10x Genomics | Reiterates: Overweight | $14 | $9.42 | +48.62% | 6 | May 15, 2025 | |
| HOLX Hologic | Maintains: Overweight | $77 → $70 | $64.33 | +8.81% | 4 | May 13, 2025 | |
| CDNA CareDx | Reiterates: Overweight | $40 | $19.49 | +105.23% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $92.99 | +23.67% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $27.46 | +63.87% | 7 | Mar 26, 2025 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $2.97 | +34.68% | 5 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $48.06 | +14.44% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.16 | +55.17% | 6 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $3.44 | +74.42% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $17.89 | -4.95% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $52 | $38.11 | +36.45% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $5.09 | +292.93% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $17.60 | +132.95% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $163.76 | -23.67% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $7.42 | +156.06% | 1 | Jul 30, 2024 | |
Vericel
May 22, 2025
Reiterates: Overweight
Price Target: $67
Current: $43.30
Upside: +54.73%
Illumina
May 20, 2025
Reiterates: Overweight
Price Target: $105
Current: $82.66
Upside: +27.03%
Pacific Biosciences of California
May 15, 2025
Reiterates: Overweight
Price Target: $1.8
Current: $1.14
Upside: +57.89%
10x Genomics
May 15, 2025
Reiterates: Overweight
Price Target: $14
Current: $9.42
Upside: +48.62%
Hologic
May 13, 2025
Maintains: Overweight
Price Target: $77 → $70
Current: $64.33
Upside: +8.81%
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $19.49
Upside: +105.23%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $92.99
Upside: +23.67%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $27.46
Upside: +63.87%
OncoCyte
Mar 26, 2025
Reiterates: Equal-Weight
Price Target: $4
Current: $2.97
Upside: +34.68%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $48.06
Upside: +14.44%
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.16
Upside: +55.17%
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $3.44
Upside: +74.42%
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $17.89
Upside: -4.95%
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $38.11
Upside: +36.45%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $5.09
Upside: +292.93%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $17.60
Upside: +132.95%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $163.76
Upside: -23.67%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $7.42
Upside: +156.06%